These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 11860528)
1. Serum uric acid levels: a useful but not absolute marker of compliance with fenofibrate treatment. Kiortsis DN; Elisaf MS Fundam Clin Pharmacol; 2001 Dec; 15(6):401-3. PubMed ID: 11860528 [TBL] [Abstract][Full Text] [Related]
2. Comparison of the efficacy of atorvastatin and micronized fenofibrate in the treatment of mixed hyperlipidemia. Bairaktari ET; Tzallas CS; Tsimihodimos VK; Liberopoulos EN; Miltiadous GA; Elisaf MS J Cardiovasc Risk; 1999 Apr; 6(2):113-6. PubMed ID: 10353071 [TBL] [Abstract][Full Text] [Related]
3. [Effects of micronized fenofibrate on lipid and uric acid metabolism in patients with hyperlipidemia]. Li LJ; Chen H; Ren JY; Wang L; Luo Y Beijing Da Xue Xue Bao Yi Xue Ban; 2009 Oct; 41(5):541-4. PubMed ID: 19829670 [TBL] [Abstract][Full Text] [Related]
4. The effects of the addition of micronised fenofibrate on uric acid metabolism in patients receiving indapamide. Achimastos A; Liberopoulos E; Nikas S; Bairaktari E; Miltiadous G; Tsimihodimos V; Elisaf M Curr Med Res Opin; 2002; 18(2):59-63. PubMed ID: 12017210 [TBL] [Abstract][Full Text] [Related]
5. Efficacy of combination of atorvastatin and micronised fenofibrate in the treatment of severe mixed hyperlipidemia. Kiortisis DN; Millionis H; Bairaktari E; Elisaf MS Eur J Clin Pharmacol; 2000 Dec; 56(9-10):631-5. PubMed ID: 11214768 [TBL] [Abstract][Full Text] [Related]
6. Effect of fenofibrate on uric acid metabolism in Japanese hyperlipidemic patients. Noguchi Y; Tatsuno I; Suyama K; Shibata T; Yoshida T; Otsuka Y; Fuse M; Takeo C; Saito Y J Atheroscler Thromb; 2004; 11(6):335-40. PubMed ID: 15644587 [TBL] [Abstract][Full Text] [Related]
7. Comparative effects of atorvastatin, simvastatin, and fenofibrate on serum homocysteine levels in patients with primary hyperlipidemia. Milionis HJ; Papakostas J; Kakafika A; Chasiotis G; Seferiadis K; Elisaf MS J Clin Pharmacol; 2003 Aug; 43(8):825-30. PubMed ID: 12953339 [TBL] [Abstract][Full Text] [Related]
8. Effect of micronized fenofibrate and losartan combination on uric acid metabolism in hypertensive patients with hyperuricemia. Elisaf M; Tsimichodimos V; Bairaktari E; Siamopoulos KC J Cardiovasc Pharmacol; 1999 Jul; 34(1):60-3. PubMed ID: 10413068 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of fenofibrate or gemfibrozil on serum lipid profiles in Chinese patients with type IIb hyperlipidemia: a single-blind, randomized, and cross-over study. Jen SL; Chen JW; Lee WL; Wang SP Zhonghua Yi Xue Za Zhi (Taipei); 1997 Apr; 59(4):217-24. PubMed ID: 9216117 [TBL] [Abstract][Full Text] [Related]
10. Effect of fenofibrate on serum uric acid levels. Liamis G; Bairaktari ET; Elisaf MS Am J Kidney Dis; 1999 Sep; 34(3):594. PubMed ID: 10469875 [No Abstract] [Full Text] [Related]
11. Efficacy and tolerability of a "suprabioavailable" formulation of fenofibrate in patients with dyslipidemia: a pooled analysis of two open-label trials. Ramjattan BR; Callaghan DJ; Theiss U Clin Ther; 2002 Jul; 24(7):1105-16. PubMed ID: 12182255 [TBL] [Abstract][Full Text] [Related]
12. A retrospective assessment of the effectiveness of fenofibrate 267 mg on high-density lipoprotein cholesterol levels in patients attending a lipid clinic. le Roux CW; Murphy E; Seed M Clin Ther; 2002 Jul; 24(7):1154-60. PubMed ID: 12182259 [TBL] [Abstract][Full Text] [Related]
13. Effects of micronized fenofibrate versus atorvastatin in the treatment of dyslipidaemic patients with low plasma HDL-cholesterol levels: a 12-week randomized trial. Després JP; Lemieux I; Salomon H; Delaval D J Intern Med; 2002 Jun; 251(6):490-9. PubMed ID: 12028504 [TBL] [Abstract][Full Text] [Related]
14. Micronized fenofibrate in dyslipidemia: a focus on plasma high-density lipoprotein cholesterol (HDL-C) levels. Sharpe M; Ormrod D; Jarvis B Am J Cardiovasc Drugs; 2002; 2(2):125-32; discussion 133-4. PubMed ID: 14727988 [TBL] [Abstract][Full Text] [Related]
15. Effects of fenofibrate and ezetimibe, both as monotherapy and in coadministration, on cholesterol mass within lipoprotein subfractions and low-density lipoprotein peak particle size in patients with mixed hyperlipidemia. Tribble DL; Farnier M; Macdonell G; Perevozskaya I; Davies MJ; Gumbiner B; Musliner TA Metabolism; 2008 Jun; 57(6):796-801. PubMed ID: 18502262 [TBL] [Abstract][Full Text] [Related]
16. Fenofibrate in the treatment of dyslipidemia: a review of the data as they relate to the new suprabioavailable tablet formulation. Najib J Clin Ther; 2002 Dec; 24(12):2022-50. PubMed ID: 12581543 [TBL] [Abstract][Full Text] [Related]
17. [Lipid lowering, antiinflammatory, and vasoprotective effects of fenofibrate in patients with type 2 diabetes mellitus]. Tkacheva ON; Sharashkina NV; Novikova IM; Torshkhoeva KhM Kardiologiia; 2010; 50(5):36-41. PubMed ID: 20831046 [TBL] [Abstract][Full Text] [Related]
18. [Micronized fenofibrate, decreased triglyceride levels, total cholesterol and LDL fractions in serum]. Zaborska B; Kłoś J; Sikora-Frac M; Cybulska B; Ceremuzyński L Pol Arch Med Wewn; 2000 Jul; 104(1):371-5. PubMed ID: 11303327 [TBL] [Abstract][Full Text] [Related]
19. Contribution of apo CIII reduction to the greater effect of 12-week micronized fenofibrate than atorvastatin therapy on triglyceride levels and LDL size in dyslipidemic patients. Lemieux I; Salomon H; Després JP Ann Med; 2003; 35(6):442-8. PubMed ID: 14572169 [TBL] [Abstract][Full Text] [Related]
20. Fenofibrate effect on triglyceride and postprandial response of apolipoprotein A5 variants: the GOLDN study. Lai CQ; Arnett DK; Corella D; Straka RJ; Tsai MY; Peacock JM; Adiconis X; Parnell LD; Hixson JE; Province MA; Ordovas JM Arterioscler Thromb Vasc Biol; 2007 Jun; 27(6):1417-25. PubMed ID: 17431185 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]